nodes	percent_of_prediction	percent_of_DWPC	metapath
Zileuton—CYP1A2—Imiquimod—skin cancer	0.159	0.206	CbGbCtD
Zileuton—CYP2C9—Vismodegib—skin cancer	0.0991	0.129	CbGbCtD
Zileuton—CYP1A2—Vemurafenib—skin cancer	0.087	0.113	CbGbCtD
Zileuton—CYP3A4—Temozolomide—skin cancer	0.0832	0.108	CbGbCtD
Zileuton—CYP3A4—Imiquimod—skin cancer	0.0832	0.108	CbGbCtD
Zileuton—CYP1A2—Dacarbazine—skin cancer	0.0667	0.0865	CbGbCtD
Zileuton—CYP3A4—Vismodegib—skin cancer	0.0576	0.0748	CbGbCtD
Zileuton—CYP3A4—Vemurafenib—skin cancer	0.0456	0.0591	CbGbCtD
Zileuton—CYP1A2—Fluorouracil—skin cancer	0.0391	0.0507	CbGbCtD
Zileuton—CYP2C9—Fluorouracil—skin cancer	0.0352	0.0457	CbGbCtD
Zileuton—CYP3A4—Docetaxel—skin cancer	0.0156	0.0203	CbGbCtD
Zileuton—White blood cell count decreased—Imiquimod—skin cancer	0.00613	0.0336	CcSEcCtD
Zileuton—LTB4R—nipple—skin cancer	0.00531	0.154	CbGeAlD
Zileuton—Traumatic liver injury—Temozolomide—skin cancer	0.00491	0.0269	CcSEcCtD
Zileuton—Hepatotoxicity—Vemurafenib—skin cancer	0.00463	0.0254	CcSEcCtD
Zileuton—Pharyngolaryngeal pain—Imiquimod—skin cancer	0.00452	0.0248	CcSEcCtD
Zileuton—Laryngeal pain—Imiquimod—skin cancer	0.00447	0.0245	CcSEcCtD
Zileuton—Abdominal pain upper—Vismodegib—skin cancer	0.00384	0.021	CcSEcCtD
Zileuton—LTB4R—skin of body—skin cancer	0.0034	0.0986	CbGeAlD
Zileuton—LTB4R—mammalian vulva—skin cancer	0.0031	0.0899	CbGeAlD
Zileuton—Vaginal inflammation—Imiquimod—skin cancer	0.00305	0.0167	CcSEcCtD
Zileuton—Vaginal infection—Imiquimod—skin cancer	0.00288	0.0158	CcSEcCtD
Zileuton—LTB4R—lymphoid tissue—skin cancer	0.00275	0.0799	CbGeAlD
Zileuton—Hepatotoxicity—Dactinomycin—skin cancer	0.00262	0.0143	CcSEcCtD
Zileuton—Lymphadenopathy—Imiquimod—skin cancer	0.00259	0.0142	CcSEcCtD
Zileuton—Hepatotoxicity—Temozolomide—skin cancer	0.00237	0.013	CcSEcCtD
Zileuton—EPHX2—mammalian vulva—skin cancer	0.00228	0.0662	CbGeAlD
Zileuton—Liver injury—Temozolomide—skin cancer	0.00217	0.0119	CcSEcCtD
Zileuton—Arthralgia—Vismodegib—skin cancer	0.00215	0.0118	CcSEcCtD
Zileuton—Myalgia—Vismodegib—skin cancer	0.00215	0.0118	CcSEcCtD
Zileuton—Hyperbilirubinaemia—Temozolomide—skin cancer	0.00201	0.011	CcSEcCtD
Zileuton—Tiaprofenic acid—PTGS2—skin cancer	0.00197	1	CrCbGaD
Zileuton—Musculoskeletal discomfort—Vismodegib—skin cancer	0.00188	0.0103	CcSEcCtD
Zileuton—Vaginal inflammation—Temozolomide—skin cancer	0.00183	0.01	CcSEcCtD
Zileuton—Dyspepsia—Vismodegib—skin cancer	0.00182	0.00996	CcSEcCtD
Zileuton—LTB4R—Eicosanoid ligand-binding receptors—PTGER4—skin cancer	0.00181	0.178	CbGpPWpGaD
Zileuton—Pharyngolaryngeal pain—Docetaxel—skin cancer	0.0018	0.00987	CcSEcCtD
Zileuton—Liver disorder—Docetaxel—skin cancer	0.00178	0.00977	CcSEcCtD
Zileuton—Laryngeal pain—Docetaxel—skin cancer	0.00178	0.00977	CcSEcCtD
Zileuton—Gastrointestinal disorder—Vismodegib—skin cancer	0.00178	0.00977	CcSEcCtD
Zileuton—Upper respiratory tract infection—Imiquimod—skin cancer	0.00178	0.00975	CcSEcCtD
Zileuton—Pain—Vismodegib—skin cancer	0.00177	0.00968	CcSEcCtD
Zileuton—Constipation—Vismodegib—skin cancer	0.00177	0.00968	CcSEcCtD
Zileuton—Vaginal infection—Temozolomide—skin cancer	0.00173	0.00946	CcSEcCtD
Zileuton—ALOX5—connective tissue—skin cancer	0.00166	0.0481	CbGeAlD
Zileuton—Conjunctivitis—Imiquimod—skin cancer	0.00166	0.00909	CcSEcCtD
Zileuton—Urinary tract infection—Imiquimod—skin cancer	0.00166	0.00909	CcSEcCtD
Zileuton—Sinusitis—Imiquimod—skin cancer	0.0016	0.00877	CcSEcCtD
Zileuton—Hepatotoxicity—Docetaxel—skin cancer	0.00157	0.00863	CcSEcCtD
Zileuton—LTB4R—lymph node—skin cancer	0.00155	0.0451	CbGeAlD
Zileuton—Pruritus—Vismodegib—skin cancer	0.00146	0.00801	CcSEcCtD
Zileuton—Diarrhoea—Vismodegib—skin cancer	0.00141	0.00774	CcSEcCtD
Zileuton—PTGS1—endothelium—skin cancer	0.00141	0.0409	CbGeAlD
Zileuton—Hyperbilirubinaemia—Docetaxel—skin cancer	0.00134	0.00733	CcSEcCtD
Zileuton—Myalgia—Vemurafenib—skin cancer	0.00133	0.00729	CcSEcCtD
Zileuton—Arthralgia—Vemurafenib—skin cancer	0.00133	0.00729	CcSEcCtD
Zileuton—Vomiting—Vismodegib—skin cancer	0.00131	0.0072	CcSEcCtD
Zileuton—Rash—Vismodegib—skin cancer	0.0013	0.00714	CcSEcCtD
Zileuton—Dermatitis—Vismodegib—skin cancer	0.0013	0.00713	CcSEcCtD
Zileuton—PTGS1—blood vessel—skin cancer	0.0013	0.0377	CbGeAlD
Zileuton—Ill-defined disorder—Imiquimod—skin cancer	0.00124	0.00678	CcSEcCtD
Zileuton—Nausea—Vismodegib—skin cancer	0.00123	0.00672	CcSEcCtD
Zileuton—ALOX5—lymphoid tissue—skin cancer	0.00121	0.0352	CbGeAlD
Zileuton—Malaise—Imiquimod—skin cancer	0.0012	0.00659	CcSEcCtD
Zileuton—ALOX5—female reproductive system—skin cancer	0.00117	0.034	CbGeAlD
Zileuton—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.00116	0.00637	CcSEcCtD
Zileuton—EPHX2—lymph node—skin cancer	0.00114	0.0331	CbGeAlD
Zileuton—Chest pain—Imiquimod—skin cancer	0.00113	0.00622	CcSEcCtD
Zileuton—Arthralgia—Imiquimod—skin cancer	0.00113	0.00622	CcSEcCtD
Zileuton—Myalgia—Imiquimod—skin cancer	0.00113	0.00622	CcSEcCtD
Zileuton—Discomfort—Imiquimod—skin cancer	0.00112	0.00615	CcSEcCtD
Zileuton—Gastrointestinal disorder—Vemurafenib—skin cancer	0.0011	0.00604	CcSEcCtD
Zileuton—Constipation—Vemurafenib—skin cancer	0.00109	0.00598	CcSEcCtD
Zileuton—CYP1A2—nipple—skin cancer	0.00108	0.0314	CbGeAlD
Zileuton—Upper respiratory tract infection—Temozolomide—skin cancer	0.00107	0.00584	CcSEcCtD
Zileuton—Hepatitis—Dactinomycin—skin cancer	0.00101	0.00556	CcSEcCtD
Zileuton—Body temperature increased—Vemurafenib—skin cancer	0.00101	0.00553	CcSEcCtD
Zileuton—Urinary tract infection—Temozolomide—skin cancer	0.000994	0.00545	CcSEcCtD
Zileuton—Musculoskeletal discomfort—Imiquimod—skin cancer	0.000991	0.00543	CcSEcCtD
Zileuton—Insomnia—Imiquimod—skin cancer	0.000984	0.00539	CcSEcCtD
Zileuton—Upper respiratory tract infection—Fluorouracil—skin cancer	0.000982	0.00538	CcSEcCtD
Zileuton—ALOX5—head—skin cancer	0.000979	0.0284	CbGeAlD
Zileuton—Somnolence—Imiquimod—skin cancer	0.000967	0.0053	CcSEcCtD
Zileuton—Sinusitis—Temozolomide—skin cancer	0.000959	0.00526	CcSEcCtD
Zileuton—Dyspepsia—Imiquimod—skin cancer	0.000958	0.00525	CcSEcCtD
Zileuton—PTGS1—nipple—skin cancer	0.00094	0.0272	CbGeAlD
Zileuton—Hypersensitivity—Vemurafenib—skin cancer	0.00094	0.00515	CcSEcCtD
Zileuton—Gastrointestinal disorder—Imiquimod—skin cancer	0.000939	0.00515	CcSEcCtD
Zileuton—Pain—Imiquimod—skin cancer	0.00093	0.0051	CcSEcCtD
Zileuton—Hepatitis—Temozolomide—skin cancer	0.000918	0.00503	CcSEcCtD
Zileuton—Conjunctivitis—Fluorouracil—skin cancer	0.000916	0.00502	CcSEcCtD
Zileuton—Urinary tract infection—Fluorouracil—skin cancer	0.000916	0.00502	CcSEcCtD
Zileuton—Pruritus—Vemurafenib—skin cancer	0.000903	0.00495	CcSEcCtD
Zileuton—Feeling abnormal—Imiquimod—skin cancer	0.000897	0.00491	CcSEcCtD
Zileuton—Sinusitis—Fluorouracil—skin cancer	0.000884	0.00484	CcSEcCtD
Zileuton—Ill-defined disorder—Bleomycin—skin cancer	0.000879	0.00482	CcSEcCtD
Zileuton—Diarrhoea—Vemurafenib—skin cancer	0.000873	0.00478	CcSEcCtD
Zileuton—Urticaria—Imiquimod—skin cancer	0.000864	0.00474	CcSEcCtD
Zileuton—Body temperature increased—Imiquimod—skin cancer	0.00086	0.00471	CcSEcCtD
Zileuton—Malaise—Bleomycin—skin cancer	0.000854	0.00468	CcSEcCtD
Zileuton—Dizziness—Vemurafenib—skin cancer	0.000844	0.00462	CcSEcCtD
Zileuton—Ill-defined disorder—Dactinomycin—skin cancer	0.00082	0.00449	CcSEcCtD
Zileuton—Vomiting—Vemurafenib—skin cancer	0.000811	0.00445	CcSEcCtD
Zileuton—Chest pain—Bleomycin—skin cancer	0.000806	0.00442	CcSEcCtD
Zileuton—Myalgia—Bleomycin—skin cancer	0.000806	0.00442	CcSEcCtD
Zileuton—Abdominal pain upper—Docetaxel—skin cancer	0.000806	0.00442	CcSEcCtD
Zileuton—Rash—Vemurafenib—skin cancer	0.000804	0.00441	CcSEcCtD
Zileuton—Dermatitis—Vemurafenib—skin cancer	0.000804	0.00441	CcSEcCtD
Zileuton—Hypersensitivity—Imiquimod—skin cancer	0.000802	0.00439	CcSEcCtD
Zileuton—Headache—Vemurafenib—skin cancer	0.000799	0.00438	CcSEcCtD
Zileuton—Discomfort—Bleomycin—skin cancer	0.000797	0.00437	CcSEcCtD
Zileuton—Malaise—Dactinomycin—skin cancer	0.000797	0.00437	CcSEcCtD
Zileuton—Pruritus—Imiquimod—skin cancer	0.00077	0.00422	CcSEcCtD
Zileuton—Nausea—Vemurafenib—skin cancer	0.000758	0.00415	CcSEcCtD
Zileuton—Myalgia—Dactinomycin—skin cancer	0.000752	0.00412	CcSEcCtD
Zileuton—Diarrhoea—Imiquimod—skin cancer	0.000744	0.00408	CcSEcCtD
Zileuton—Discomfort—Dactinomycin—skin cancer	0.000743	0.00407	CcSEcCtD
Zileuton—Ill-defined disorder—Temozolomide—skin cancer	0.000741	0.00406	CcSEcCtD
Zileuton—Malaise—Temozolomide—skin cancer	0.00072	0.00395	CcSEcCtD
Zileuton—Dizziness—Imiquimod—skin cancer	0.000719	0.00394	CcSEcCtD
Zileuton—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000704	0.00386	CcSEcCtD
Zileuton—Vomiting—Imiquimod—skin cancer	0.000692	0.00379	CcSEcCtD
Zileuton—Rash—Imiquimod—skin cancer	0.000686	0.00376	CcSEcCtD
Zileuton—Dermatitis—Imiquimod—skin cancer	0.000685	0.00376	CcSEcCtD
Zileuton—ALOX5—lymph node—skin cancer	0.000685	0.0199	CbGeAlD
Zileuton—Headache—Imiquimod—skin cancer	0.000682	0.00374	CcSEcCtD
Zileuton—Arthralgia—Temozolomide—skin cancer	0.00068	0.00373	CcSEcCtD
Zileuton—Myalgia—Temozolomide—skin cancer	0.00068	0.00373	CcSEcCtD
Zileuton—Discomfort—Temozolomide—skin cancer	0.000672	0.00368	CcSEcCtD
Zileuton—PTGS1—connective tissue—skin cancer	0.000667	0.0193	CbGeAlD
Zileuton—Jaundice—Docetaxel—skin cancer	0.000663	0.00363	CcSEcCtD
Zileuton—Pain—Bleomycin—skin cancer	0.000661	0.00362	CcSEcCtD
Zileuton—Conjunctivitis—Docetaxel—skin cancer	0.000661	0.00362	CcSEcCtD
Zileuton—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000657	0.0036	CcSEcCtD
Zileuton—Nausea—Imiquimod—skin cancer	0.000646	0.00354	CcSEcCtD
Zileuton—Feeling abnormal—Bleomycin—skin cancer	0.000637	0.00349	CcSEcCtD
Zileuton—PTGS1—epithelium—skin cancer	0.000633	0.0183	CbGeAlD
Zileuton—Myalgia—Fluorouracil—skin cancer	0.000627	0.00343	CcSEcCtD
Zileuton—Chest pain—Fluorouracil—skin cancer	0.000627	0.00343	CcSEcCtD
Zileuton—Discomfort—Fluorouracil—skin cancer	0.000619	0.00339	CcSEcCtD
Zileuton—Pain—Dactinomycin—skin cancer	0.000616	0.00338	CcSEcCtD
Zileuton—Urticaria—Bleomycin—skin cancer	0.000614	0.00337	CcSEcCtD
Zileuton—Body temperature increased—Bleomycin—skin cancer	0.000611	0.00335	CcSEcCtD
Zileuton—Hepatitis—Docetaxel—skin cancer	0.00061	0.00335	CcSEcCtD
Zileuton—PTGS1—skin of body—skin cancer	0.000602	0.0175	CbGeAlD
Zileuton—Feeling abnormal—Dactinomycin—skin cancer	0.000594	0.00326	CcSEcCtD
Zileuton—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000594	0.00326	CcSEcCtD
Zileuton—Insomnia—Temozolomide—skin cancer	0.00059	0.00323	CcSEcCtD
Zileuton—Somnolence—Temozolomide—skin cancer	0.00058	0.00318	CcSEcCtD
Zileuton—Dyspepsia—Temozolomide—skin cancer	0.000574	0.00315	CcSEcCtD
Zileuton—Body temperature increased—Dactinomycin—skin cancer	0.00057	0.00312	CcSEcCtD
Zileuton—Hypersensitivity—Bleomycin—skin cancer	0.000569	0.00312	CcSEcCtD
Zileuton—Gastrointestinal disorder—Temozolomide—skin cancer	0.000563	0.00309	CcSEcCtD
Zileuton—Pain—Temozolomide—skin cancer	0.000558	0.00306	CcSEcCtD
Zileuton—Constipation—Temozolomide—skin cancer	0.000558	0.00306	CcSEcCtD
Zileuton—LTB4R—Spinal Cord Injury—CSPG4—skin cancer	0.000554	0.0546	CbGpPWpGaD
Zileuton—PTGS1—mammalian vulva—skin cancer	0.000549	0.0159	CbGeAlD
Zileuton—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000547	0.003	CcSEcCtD
Zileuton—Pruritus—Bleomycin—skin cancer	0.000547	0.003	CcSEcCtD
Zileuton—Insomnia—Fluorouracil—skin cancer	0.000543	0.00298	CcSEcCtD
Zileuton—Feeling abnormal—Temozolomide—skin cancer	0.000537	0.00295	CcSEcCtD
Zileuton—Somnolence—Fluorouracil—skin cancer	0.000534	0.00293	CcSEcCtD
Zileuton—Hypersensitivity—Dactinomycin—skin cancer	0.000531	0.00291	CcSEcCtD
Zileuton—Dyspepsia—Fluorouracil—skin cancer	0.000529	0.0029	CcSEcCtD
Zileuton—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000519	0.00284	CcSEcCtD
Zileuton—Urticaria—Temozolomide—skin cancer	0.000518	0.00284	CcSEcCtD
Zileuton—Body temperature increased—Temozolomide—skin cancer	0.000515	0.00283	CcSEcCtD
Zileuton—CYP2C9—female reproductive system—skin cancer	0.000515	0.0149	CbGeAlD
Zileuton—Pain—Fluorouracil—skin cancer	0.000514	0.00282	CcSEcCtD
Zileuton—Feeling abnormal—Fluorouracil—skin cancer	0.000495	0.00271	CcSEcCtD
Zileuton—Diarrhoea—Dactinomycin—skin cancer	0.000493	0.0027	CcSEcCtD
Zileuton—Vomiting—Bleomycin—skin cancer	0.000491	0.00269	CcSEcCtD
Zileuton—Rash—Bleomycin—skin cancer	0.000487	0.00267	CcSEcCtD
Zileuton—Dermatitis—Bleomycin—skin cancer	0.000487	0.00267	CcSEcCtD
Zileuton—Hypersensitivity—Temozolomide—skin cancer	0.00048	0.00263	CcSEcCtD
Zileuton—Urticaria—Fluorouracil—skin cancer	0.000477	0.00262	CcSEcCtD
Zileuton—Body temperature increased—Fluorouracil—skin cancer	0.000475	0.0026	CcSEcCtD
Zileuton—PTGS1—female reproductive system—skin cancer	0.00047	0.0136	CbGeAlD
Zileuton—Pruritus—Temozolomide—skin cancer	0.000461	0.00253	CcSEcCtD
Zileuton—Nausea—Bleomycin—skin cancer	0.000459	0.00252	CcSEcCtD
Zileuton—Vomiting—Dactinomycin—skin cancer	0.000458	0.00251	CcSEcCtD
Zileuton—Rash—Dactinomycin—skin cancer	0.000455	0.00249	CcSEcCtD
Zileuton—Arthralgia—Docetaxel—skin cancer	0.000452	0.00248	CcSEcCtD
Zileuton—Chest pain—Docetaxel—skin cancer	0.000452	0.00248	CcSEcCtD
Zileuton—Myalgia—Docetaxel—skin cancer	0.000452	0.00248	CcSEcCtD
Zileuton—Diarrhoea—Temozolomide—skin cancer	0.000446	0.00245	CcSEcCtD
Zileuton—Hypersensitivity—Fluorouracil—skin cancer	0.000443	0.00243	CcSEcCtD
Zileuton—Dizziness—Temozolomide—skin cancer	0.000431	0.00236	CcSEcCtD
Zileuton—Nausea—Dactinomycin—skin cancer	0.000428	0.00235	CcSEcCtD
Zileuton—Pruritus—Fluorouracil—skin cancer	0.000425	0.00233	CcSEcCtD
Zileuton—Vomiting—Temozolomide—skin cancer	0.000415	0.00227	CcSEcCtD
Zileuton—Rash—Temozolomide—skin cancer	0.000411	0.00225	CcSEcCtD
Zileuton—Diarrhoea—Fluorouracil—skin cancer	0.000411	0.00225	CcSEcCtD
Zileuton—Dermatitis—Temozolomide—skin cancer	0.000411	0.00225	CcSEcCtD
Zileuton—Headache—Temozolomide—skin cancer	0.000408	0.00224	CcSEcCtD
Zileuton—Dizziness—Fluorouracil—skin cancer	0.000397	0.00218	CcSEcCtD
Zileuton—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000395	0.00217	CcSEcCtD
Zileuton—PTGS1—head—skin cancer	0.000393	0.0114	CbGeAlD
Zileuton—CYP3A4—female reproductive system—skin cancer	0.000393	0.0114	CbGeAlD
Zileuton—Insomnia—Docetaxel—skin cancer	0.000392	0.00215	CcSEcCtD
Zileuton—Nausea—Temozolomide—skin cancer	0.000387	0.00212	CcSEcCtD
Zileuton—Somnolence—Docetaxel—skin cancer	0.000385	0.00211	CcSEcCtD
Zileuton—Vomiting—Fluorouracil—skin cancer	0.000382	0.00209	CcSEcCtD
Zileuton—Dyspepsia—Docetaxel—skin cancer	0.000382	0.00209	CcSEcCtD
Zileuton—Rash—Fluorouracil—skin cancer	0.000379	0.00208	CcSEcCtD
Zileuton—Dermatitis—Fluorouracil—skin cancer	0.000378	0.00207	CcSEcCtD
Zileuton—Headache—Fluorouracil—skin cancer	0.000376	0.00206	CcSEcCtD
Zileuton—Gastrointestinal disorder—Docetaxel—skin cancer	0.000374	0.00205	CcSEcCtD
Zileuton—Pain—Docetaxel—skin cancer	0.000371	0.00203	CcSEcCtD
Zileuton—Constipation—Docetaxel—skin cancer	0.000371	0.00203	CcSEcCtD
Zileuton—Feeling abnormal—Docetaxel—skin cancer	0.000357	0.00196	CcSEcCtD
Zileuton—Nausea—Fluorouracil—skin cancer	0.000357	0.00196	CcSEcCtD
Zileuton—Body temperature increased—Docetaxel—skin cancer	0.000343	0.00188	CcSEcCtD
Zileuton—Hypersensitivity—Docetaxel—skin cancer	0.000319	0.00175	CcSEcCtD
Zileuton—Pruritus—Docetaxel—skin cancer	0.000307	0.00168	CcSEcCtD
Zileuton—Diarrhoea—Docetaxel—skin cancer	0.000297	0.00163	CcSEcCtD
Zileuton—Dizziness—Docetaxel—skin cancer	0.000287	0.00157	CcSEcCtD
Zileuton—LTB4R—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.000283	0.0278	CbGpPWpGaD
Zileuton—Vomiting—Docetaxel—skin cancer	0.000276	0.00151	CcSEcCtD
Zileuton—PTGS1—lymph node—skin cancer	0.000275	0.00797	CbGeAlD
Zileuton—Rash—Docetaxel—skin cancer	0.000273	0.0015	CcSEcCtD
Zileuton—Dermatitis—Docetaxel—skin cancer	0.000273	0.0015	CcSEcCtD
Zileuton—Headache—Docetaxel—skin cancer	0.000272	0.00149	CcSEcCtD
Zileuton—ALOX5—Eicosanoid Synthesis—PTGS2—skin cancer	0.000261	0.0257	CbGpPWpGaD
Zileuton—EPHX2—Arachidonic acid metabolism—PTGS2—skin cancer	0.000261	0.0257	CbGpPWpGaD
Zileuton—Nausea—Docetaxel—skin cancer	0.000258	0.00141	CcSEcCtD
Zileuton—LTB4R—GPCR ligand binding—PTCH2—skin cancer	0.000255	0.0251	CbGpPWpGaD
Zileuton—PTGS1—Prostaglandin Synthesis and Regulation—PTGER4—skin cancer	0.000251	0.0247	CbGpPWpGaD
Zileuton—LTB4R—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.000242	0.0239	CbGpPWpGaD
Zileuton—UGT1A9—PPARA activates gene expression—PLIN2—skin cancer	0.000215	0.0212	CbGpPWpGaD
Zileuton—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PLIN2—skin cancer	0.000211	0.0207	CbGpPWpGaD
Zileuton—EPHX2—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	0.000195	0.0192	CbGpPWpGaD
Zileuton—LTB4R—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.000186	0.0183	CbGpPWpGaD
Zileuton—LTB4R—GPCR ligand binding—MC1R—skin cancer	0.000184	0.0182	CbGpPWpGaD
Zileuton—LTB4R—Spinal Cord Injury—CDK4—skin cancer	0.000184	0.0181	CbGpPWpGaD
Zileuton—UGT1A9—PPAR Alpha Pathway—CDK4—skin cancer	0.000182	0.0179	CbGpPWpGaD
Zileuton—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—skin cancer	0.000174	0.0172	CbGpPWpGaD
Zileuton—LTB4R—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.000159	0.0157	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—RHOU—skin cancer	0.000158	0.0156	CbGpPWpGaD
Zileuton—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—PLIN2—skin cancer	0.000145	0.0143	CbGpPWpGaD
Zileuton—ALOX5—Arachidonic acid metabolism—PTGS2—skin cancer	0.000145	0.0143	CbGpPWpGaD
Zileuton—PTGS1—Overview of nanoparticle effects—PTGS2—skin cancer	0.000136	0.0134	CbGpPWpGaD
Zileuton—LTB4R—GPCR ligand binding—SHH—skin cancer	0.000131	0.0129	CbGpPWpGaD
Zileuton—LTB4R—Spinal Cord Injury—PTGS2—skin cancer	0.000131	0.0129	CbGpPWpGaD
Zileuton—LTB4R—Signaling by GPCR—PTCH2—skin cancer	0.000131	0.0129	CbGpPWpGaD
Zileuton—LTB4R—GPCR ligand binding—PTCH1—skin cancer	0.000125	0.0123	CbGpPWpGaD
Zileuton—LTB4R—GPCR ligand binding—SMO—skin cancer	0.000125	0.0123	CbGpPWpGaD
Zileuton—LTB4R—GPCR ligand binding—PTGER4—skin cancer	0.000121	0.0119	CbGpPWpGaD
Zileuton—PTGS1—Eicosanoid Synthesis—PTGS2—skin cancer	0.000113	0.0111	CbGpPWpGaD
Zileuton—ALOX5—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	0.000109	0.0107	CbGpPWpGaD
Zileuton—LTB4R—GPCR downstream signaling—MC1R—skin cancer	0.000104	0.0103	CbGpPWpGaD
Zileuton—LTB4R—Signaling by GPCR—MC1R—skin cancer	9.47e-05	0.00932	CbGpPWpGaD
Zileuton—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—skin cancer	9.47e-05	0.00932	CbGpPWpGaD
Zileuton—ALOX5—Selenium Micronutrient Network—PTGS2—skin cancer	9.23e-05	0.00909	CbGpPWpGaD
Zileuton—EPHX2—Metabolism—PLIN2—skin cancer	8.7e-05	0.00857	CbGpPWpGaD
Zileuton—LTB4R—Spinal Cord Injury—TP53—skin cancer	7.81e-05	0.00769	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—PTCH2—skin cancer	7.74e-05	0.00762	CbGpPWpGaD
Zileuton—PTGS1—Overview of nanoparticle effects—IL6—skin cancer	7.43e-05	0.00732	CbGpPWpGaD
Zileuton—LTB4R—Spinal Cord Injury—IL6—skin cancer	7.15e-05	0.00704	CbGpPWpGaD
Zileuton—EPHX2—Metabolism—CSPG4—skin cancer	7.01e-05	0.00691	CbGpPWpGaD
Zileuton—LTB4R—GPCR downstream signaling—PTGER4—skin cancer	6.86e-05	0.00675	CbGpPWpGaD
Zileuton—LTB4R—Signaling by GPCR—SHH—skin cancer	6.75e-05	0.00664	CbGpPWpGaD
Zileuton—LTB4R—Signaling by GPCR—SMO—skin cancer	6.4e-05	0.0063	CbGpPWpGaD
Zileuton—LTB4R—Signaling by GPCR—PTCH1—skin cancer	6.4e-05	0.0063	CbGpPWpGaD
Zileuton—LTB4R—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	6.32e-05	0.00622	CbGpPWpGaD
Zileuton—PTGS1—Arachidonic acid metabolism—PTGS2—skin cancer	6.29e-05	0.0062	CbGpPWpGaD
Zileuton—LTB4R—Signaling by GPCR—PTGER4—skin cancer	6.23e-05	0.00613	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—GLI2—skin cancer	5.86e-05	0.00577	CbGpPWpGaD
Zileuton—UGT1A9—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	5.78e-05	0.00569	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—MC1R—skin cancer	5.59e-05	0.00551	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—GLI1—skin cancer	5.51e-05	0.00543	CbGpPWpGaD
Zileuton—LTB4R—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	5.44e-05	0.00535	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—SUFU—skin cancer	5.23e-05	0.00515	CbGpPWpGaD
Zileuton—ALOX5—Selenium Micronutrient Network—IL6—skin cancer	5.03e-05	0.00495	CbGpPWpGaD
Zileuton—ALOX5—Metabolism—PLIN2—skin cancer	4.84e-05	0.00477	CbGpPWpGaD
Zileuton—EPHX2—Metabolism—ENO2—skin cancer	4.77e-05	0.00469	CbGpPWpGaD
Zileuton—PTGS1—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	4.71e-05	0.00464	CbGpPWpGaD
Zileuton—LTB4R—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	4.62e-05	0.00455	CbGpPWpGaD
Zileuton—LTB4R—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	4.42e-05	0.00436	CbGpPWpGaD
Zileuton—PTGS1—Selenium Micronutrient Network—PTGS2—skin cancer	4e-05	0.00394	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—SHH—skin cancer	3.99e-05	0.00392	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—RASA1—skin cancer	3.96e-05	0.0039	CbGpPWpGaD
Zileuton—ALOX5—Metabolism—CSPG4—skin cancer	3.9e-05	0.00384	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—PTCH1—skin cancer	3.78e-05	0.00372	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—SMO—skin cancer	3.78e-05	0.00372	CbGpPWpGaD
Zileuton—EPHX2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	3.73e-05	0.00367	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—PTGER4—skin cancer	3.68e-05	0.00362	CbGpPWpGaD
Zileuton—CYP2C9—Arachidonic acid metabolism—PTGS2—skin cancer	3.31e-05	0.00326	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—FOXO4—skin cancer	3.25e-05	0.0032	CbGpPWpGaD
Zileuton—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—skin cancer	3.02e-05	0.00298	CbGpPWpGaD
Zileuton—CYP1A2—Arachidonic acid metabolism—PTGS2—skin cancer	2.83e-05	0.00278	CbGpPWpGaD
Zileuton—EPHX2—Metabolism—ERCC2—skin cancer	2.77e-05	0.00273	CbGpPWpGaD
Zileuton—ALOX5—Metabolism—ENO2—skin cancer	2.65e-05	0.00261	CbGpPWpGaD
Zileuton—UGT1A9—Metabolism—PLIN2—skin cancer	2.57e-05	0.00253	CbGpPWpGaD
Zileuton—CYP2C9—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	2.48e-05	0.00244	CbGpPWpGaD
Zileuton—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—skin cancer	2.35e-05	0.00231	CbGpPWpGaD
Zileuton—PTGS1—Selenium Micronutrient Network—IL6—skin cancer	2.18e-05	0.00215	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—TERT—skin cancer	2.17e-05	0.00214	CbGpPWpGaD
Zileuton—CYP1A2—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	2.12e-05	0.00208	CbGpPWpGaD
Zileuton—PTGS1—Metabolism—PLIN2—skin cancer	2.1e-05	0.00207	CbGpPWpGaD
Zileuton—UGT1A9—Metabolism—CSPG4—skin cancer	2.07e-05	0.00204	CbGpPWpGaD
Zileuton—ALOX5—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	2.07e-05	0.00204	CbGpPWpGaD
Zileuton—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—skin cancer	2.02e-05	0.00199	CbGpPWpGaD
Zileuton—LTB4R—Signaling by GPCR—NRAS—skin cancer	1.83e-05	0.0018	CbGpPWpGaD
Zileuton—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—skin cancer	1.72e-05	0.00169	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—BRAF—skin cancer	1.72e-05	0.00169	CbGpPWpGaD
Zileuton—PTGS1—Metabolism—CSPG4—skin cancer	1.69e-05	0.00167	CbGpPWpGaD
Zileuton—EPHX2—Metabolism—PTGS2—skin cancer	1.66e-05	0.00163	CbGpPWpGaD
Zileuton—LTB4R—Signaling by GPCR—KRAS—skin cancer	1.57e-05	0.00155	CbGpPWpGaD
Zileuton—ALOX5—Metabolism—ERCC2—skin cancer	1.54e-05	0.00152	CbGpPWpGaD
Zileuton—UGT1A9—Metabolism—ENO2—skin cancer	1.41e-05	0.00139	CbGpPWpGaD
Zileuton—LTB4R—Signaling by GPCR—HRAS—skin cancer	1.34e-05	0.00132	CbGpPWpGaD
Zileuton—LTB4R—Signaling by GPCR—IL6—skin cancer	1.28e-05	0.00126	CbGpPWpGaD
Zileuton—PTGS1—Metabolism—ENO2—skin cancer	1.15e-05	0.00113	CbGpPWpGaD
Zileuton—CYP2C9—Metabolism—PLIN2—skin cancer	1.1e-05	0.00109	CbGpPWpGaD
Zileuton—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.1e-05	0.00109	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—NRAS—skin cancer	1.08e-05	0.00106	CbGpPWpGaD
Zileuton—CYP1A2—Metabolism—PLIN2—skin cancer	9.43e-06	0.000928	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—KRAS—skin cancer	9.29e-06	0.000915	CbGpPWpGaD
Zileuton—ALOX5—Metabolism—PTGS2—skin cancer	9.23e-06	0.000909	CbGpPWpGaD
Zileuton—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	8.99e-06	0.000885	CbGpPWpGaD
Zileuton—CYP2C9—Metabolism—CSPG4—skin cancer	8.89e-06	0.000876	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—TP53—skin cancer	8.26e-06	0.000814	CbGpPWpGaD
Zileuton—UGT1A9—Metabolism—ERCC2—skin cancer	8.19e-06	0.000807	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—HRAS—skin cancer	7.9e-06	0.000778	CbGpPWpGaD
Zileuton—CYP1A2—Metabolism—CSPG4—skin cancer	7.6e-06	0.000748	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—IL6—skin cancer	7.56e-06	0.000745	CbGpPWpGaD
Zileuton—CYP3A4—Metabolism—PLIN2—skin cancer	7.27e-06	0.000716	CbGpPWpGaD
Zileuton—PTGS1—Metabolism—ERCC2—skin cancer	6.68e-06	0.000658	CbGpPWpGaD
Zileuton—CYP2C9—Metabolism—ENO2—skin cancer	6.04e-06	0.000595	CbGpPWpGaD
Zileuton—CYP3A4—Metabolism—CSPG4—skin cancer	5.86e-06	0.000577	CbGpPWpGaD
Zileuton—CYP1A2—Metabolism—ENO2—skin cancer	5.16e-06	0.000509	CbGpPWpGaD
Zileuton—UGT1A9—Metabolism—PTGS2—skin cancer	4.91e-06	0.000484	CbGpPWpGaD
Zileuton—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	4.73e-06	0.000465	CbGpPWpGaD
Zileuton—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	4.04e-06	0.000398	CbGpPWpGaD
Zileuton—PTGS1—Metabolism—PTGS2—skin cancer	4e-06	0.000394	CbGpPWpGaD
Zileuton—CYP3A4—Metabolism—ENO2—skin cancer	3.99e-06	0.000393	CbGpPWpGaD
Zileuton—CYP2C9—Metabolism—ERCC2—skin cancer	3.51e-06	0.000346	CbGpPWpGaD
Zileuton—CYP1A2—Metabolism—ERCC2—skin cancer	3e-06	0.000295	CbGpPWpGaD
Zileuton—CYP3A4—Metabolism—ERCC2—skin cancer	2.32e-06	0.000228	CbGpPWpGaD
Zileuton—CYP2C9—Metabolism—PTGS2—skin cancer	2.1e-06	0.000207	CbGpPWpGaD
Zileuton—CYP1A2—Metabolism—PTGS2—skin cancer	1.8e-06	0.000177	CbGpPWpGaD
Zileuton—CYP3A4—Metabolism—PTGS2—skin cancer	1.39e-06	0.000137	CbGpPWpGaD
